BMO Capital Markets Upgrades Envista (NYSE:NVST) to “Hold”

Envista (NYSE:NVST) was upgraded by equities researchers at BMO Capital Markets to a “hold” rating in a note issued to investors on Wednesday,Zacks.com reports.

Other equities analysts have also recently issued research reports about the stock. Weiss Ratings cut shares of Envista from a “hold (c)” rating to a “hold (c-)” rating in a research report on Monday, May 11th. Morgan Stanley upped their price target on shares of Envista from $19.00 to $21.00 and gave the company an “equal weight” rating in a research report on Friday, April 24th. Wall Street Zen cut Envista from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Evercore reiterated an “outperform” rating and issued a $33.00 price objective on shares of Envista in a report on Thursday, May 7th. Finally, Robert W. Baird boosted their target price on Envista from $30.00 to $31.00 and gave the company an “outperform” rating in a research note on Thursday, May 7th. Six equities research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. According to data from MarketBeat.com, Envista has an average rating of “Hold” and an average price target of $28.54.

Envista Stock Up 0.0%

Shares of NYSE NVST opened at $25.75 on Wednesday. Envista has a one year low of $18.77 and a one year high of $30.42. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.44 and a quick ratio of 2.06. The firm’s 50 day simple moving average is $24.84 and its two-hundred day simple moving average is $25.42. The stock has a market capitalization of $4.19 billion, a P/E ratio of 62.80, a PEG ratio of 1.46 and a beta of 0.86.

Envista (NYSE:NVST) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $0.36 earnings per share for the quarter, topping analysts’ consensus estimates of $0.31 by $0.05. Envista had a net margin of 2.41% and a return on equity of 7.11%. The firm had revenue of $705.50 million during the quarter, compared to analyst estimates of $680.03 million. During the same period in the previous year, the business posted $0.24 EPS. The business’s quarterly revenue was up 14.4% on a year-over-year basis. Envista has set its FY 2026 guidance at 1.350-1.450 EPS. As a group, analysts expect that Envista will post 1.42 EPS for the current fiscal year.

Hedge Funds Weigh In On Envista

Hedge funds and other institutional investors have recently modified their holdings of the company. Caitong International Asset Management Co. Ltd boosted its holdings in shares of Envista by 16,711.1% during the third quarter. Caitong International Asset Management Co. Ltd now owns 1,513 shares of the company’s stock worth $31,000 after purchasing an additional 1,504 shares during the period. Allworth Financial LP increased its holdings in Envista by 75.4% during the 4th quarter. Allworth Financial LP now owns 1,805 shares of the company’s stock valued at $39,000 after purchasing an additional 776 shares during the period. UMB Bank n.a. raised its position in Envista by 46.1% during the 4th quarter. UMB Bank n.a. now owns 2,017 shares of the company’s stock valued at $44,000 after purchasing an additional 636 shares during the last quarter. IFP Advisors Inc raised its position in Envista by 102.9% during the 4th quarter. IFP Advisors Inc now owns 2,112 shares of the company’s stock valued at $46,000 after purchasing an additional 1,071 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Envista by 73.1% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 2,248 shares of the company’s stock worth $44,000 after buying an additional 949 shares during the period.

Envista Company Profile

Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.

Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.